Authors: Khrystychenko M.A.
The purpose of the study was to investigate the effect of buspirone hydrochloride on QT interval dispersion (ΔQT) in patients with chronic heart failure (CHF) of ischemic etiology with anxiety and depressive disorders (ADD).
142 patients (85 males, 57 females; mean age 66.4 ± 10.5) NYHA II-IV were randomized into the study. All patients were prescribed buspirone hydrochloride 10 mg t.i.d. due to anxiety and depressive disorders. All patients had II-III functional classes of angina; 86 of them (60.6 %) had history of myocardial infarction. Randomized patients received standard CHF and coronary heart disease therapy. Informed consents were signed before the study initiation. Exclusion criteria were history of mental disorders, significant impairment of cognitive functions, alcohol/drug abuse, other psychoactive drug intake, and severe concomitant pathology.
According to the results of Hospital Anxiety and Depression Scale (HADS), Beck Depression Questionnaire and Spielberger Anxiety Scale all patients were divided into two groups: the 1st with ADD, the 2nd – without them.
Initially and in 3 months of buspirone hydrochloride intake rest ECG was recorded in 12 standard leads, 50 mm/s and QT (ΔQT) and QTc (ΔQTс) dispersions were calculated by the standard technique (DQT = QTmax – QТmin, ΔQTc = QTc max – QTc min).
Initially mean ΔQT and ΔQTc for patients of the group 1 were 58.5 ± 11.0 ms and 57.8 ± 10.4 ms, respectively, 32.0 ± 9.7 and 31.2 ± 8.6 ms for the group 2. At re-examination ΔQT had no statistically significant differences in comparison with initial data and between groups (462.3±74.1 msand 454.0 ±66.2 msforthe groups 1 and 2, respectively) (p > 0.05).
Buspirone hydrochloride treatment did not lead to increase of dispersion of ventricular repolarization in the patients with ischemic CHF.
Key words: anxiety-depressive disorders, chronic heart failure, dispersion of ventricular repolarization, buspirone hydrochloride.